FDA's Recommendation Before Clovis Submits Rubraca Application For Ovarian Cancer

Earlier this month, Clovis Oncology Inc  (NASDAQ: CLVS ) had a Type A meeting with the FDA to discuss its plans for a supplemental marketing application for Rubraca (Rucaparib) as a first-line maintenance treatment in ovarian cancer. The application, covering patients who have responded to first-line platinum-based chemotherapy, is based on the Full story available on Benzinga.com